Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing therapeutic benefit to patients dealing with chronic or debilitating disease. We are leveraging our next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
| Date | Title | | | 02/01/16 | Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger| Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT
MENLO PARK, Calif. and PARIS, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq:AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shar... |
|  | | 11/20/15 | Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO| MENLO PARK, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously th... |
| | | 11/09/15 | Avalanche Biotechnologies, Inc. Reports Third Quarter 2015 Financial Results| MENLO PARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported financial results for the third quarter ended September 30, 2015.
"We continue to make progress in our pre-clinical work across multiple disease states and in the development of our next-generation vector technology to enable new th... |
| | | 08/13/15 | Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program| MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported financial results for the second quarter ended June 30, 2015.
The company also reported that after further analyses of results from a previously reported Phase 2a trial of AVA-101 for the potential treatment of wet age-related macu... |
| |
|
